Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 171

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Immunotherapy and Novel Combinations in Oncology: Current Landscape, Challenges, and Opportunities

Open access
Morrissey, KM, Yuraszeck, TM, Li, C‐C, Zhang, Y, Kasichayanula, S·2016·Clinical and Translational Science

Abstract

Cancer treatments have been transformed with recent advances in cancer immunotherapy.1 As monotherapies, these agents have demonstrated clinical activity across many tumor types. Further advances in the effectiveness of cancer immunotherapies will require targeting antitumor immune response at multiple levels, which may be accomplished through combination approaches. This review discusses the current landscape of cancer immunotherapy, combinations in clinical development, strategies for dose selection and trial design, and clinical pharmacology and regulatory considerations. Cancer kills over 8 million people worldwide every year and the number of diagnosed cases is expected to almost double in the next two decades.2 Surgery, radiation, chemotherapy, and targeted agents are commonly used to treat these patients, but many patients either relapse or are refractory to treatment. In addition, patients and physicians must manage a variety of side effects that have a significant impact on patients' quality of life, which limits the use of these agents. It is well established that cancer cells can be recognized by the immune system, and it is hypothesized that the defeat of the immune surveillance system underlies the development of malignancies and the lack or loss of response to treatment.3, 4 Under normal circumstances, a functioning immune surveillance system will recognize and eliminate transformed cells. Ironically, this Darwinian process ultimately results in the selection of tumor cells resistant to processing by the immune system through loss of antigenicity, defects in antigen presentation, and decreased immunogenicity (e.g., through upregulation of PD1, a negative regulator of the immune system).5 Immune escape is also accomplished by the alteration of the tumor microenvironment,5 whereby tumor cells recruit immune-suppressive cells to promote conditions for their survival. Immuno-oncology approaches attempt to restore the immune surveillance system and activate the patient's immune system to fight their cancer. These approaches have garnered significant attention and are projected to be the new standard of care for diverse tumor types. Indeed, the clinical data of recent regulatory approvals of immunotherapy treatments including blinatumomab (BLINCYTO), ipilimumab (Yervoy), nivolumab (Opdivo), and pembrolizumab (Keytruda) across multiple cancer types demonstrate the clinical feasibility of this approach. The promise of immunotherapy to treat cancer was first realized over 100 years ago (Figure 1). In 1890, Emil von Behring and Erich Wernicke found that animals infected with diphtheria could be cured by injection of sera produced by animals immunized with an attenuated form of diphtheria, and this treatment was successfully used to treat a child with diphtheria in 1891.6 This introduced the use of serum as therapy and for the first time showed that immunity could be transferred, thereby demonstrating the clinical utility of passive immunity. The first application of immunotherapy in oncology also occurred in 1891, when William B. Coley (known as the father of immunotherapy) injected bacteria into a patient with cancer as a means of stimulating the immune system to shrink the patient's tumor, a strategy that was successful.7 Since then, significant progress has been made in the understanding and application of immunotherapy as monotherapy for cancer treatment. These agents can be classified as either active therapies that induce an immune response in otherwise nonresponsive patients or passive therapies that stimulate a patient's intrinsic immune response8 (Table 1). Active therapies include cytokines, immunomodulatory monoclonal antibodies (mAbs), and cancer vaccines, and passive therapies include BiTE antibody constructs, bispecific and multispecific antibodies, oncolytic viruses, cell-based therapies, and tumor-targeting mAbs. The checkpoint inhibitors (e.g., PD-1, PD-L1, CTLA-4, and LAG-3) are immunomodulatory mAbs that address immune escape by tumor cells that leverage normal immune-suppressive mechanisms to prevent autoimmunity and tissue damage in response to acute infection in otherwise healthy individuals, but promote tumor progression in cancer patients.9 BiTE antibody constructs have dual specificity for T cells and cancer cells and bind to an invariant component of a T-cell receptor and a specific surface antigen on a cancer cell (e.g., CD19), forcing them into proximity.10 Because they do not require a T-cell clone with a specific T-cell receptor or an MHC class I or peptide antigen for T-cell recognition, BiTE antibody constructs can overcome immune escape. Oncolytic viruses selectively kill cancer cells and stimulate the immune system (e.g., Imlygic), while dendritic cell vaccines (e.g., sipuleucel-T) involve the extraction of dendritic cells from the patient, exposure of those cells to cancer cells or antigens, and reintroduction of these now active immune cells to the patient (alternativ

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/cts.12391

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 171

Metadata

Authors
Morrissey, K., Yuraszeck, T., Li, C., Zhang, Y., & Kasichayanula, S.
Venue
Clinical and Translational Science
Publisher
Wiley
Published
2016-03-30
Volume
9
Issue
2
Pages
89-104
ISSN
  • 1752-8054 (ISSN-L)
  • 1752-8062
OpenAlex
W2284926981
Cited by
171
References
20
FWCI
13.75
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Immunotherapy and Novel Combinations in Oncology: Current Landscape, Challenges, and Opportunities. https://app.cochat.ai/papers/10.1111/cts.12391
The paper
Morrissey, K., Yuraszeck, T., Li, C., Zhang, Y., & Kasichayanula, S. (2016). Immunotherapy and Novel Combinations in Oncology: Current Landscape, Challenges, and Opportunities. Clinical and Translational Science. https://doi.org/10.1111/cts.12391

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.